Single-arm, dose-increasing setting study of CAR macrophages in Mesothelin overexpressing solid tumors.
Patients with pathologically diagnosed advanced ovarian cancer/pancreatic cancer who have failed at least 1 prior lines treatment, and tumor tissue samples were positive for mesothlin IHC staining;
According to the RECIST 1.1, there is measurable tumor lesions (non-lymph node lesion 10mm in length or lymph node lesion 15mm in diameter measured by CT or MRI, with scan layer thickness 5mm);
Eastern Cooperative Oncology Group (ECOG) score of 2 and satisfactory major organ functions;
Estimated life expectancy >3 months;
Pregnant or lactating women;
Any uncontrollable active infection, including but not limited to active tuberculosis, HBV infection;
Patients who have a history of other mesothelin-targeting therapy;
Patients who have a history of autoimmune disease;